“…Of note, IL-6, together with other pro-inflammatory cytokines such as Tumor Necrosis Factor-alpha (TNFa) and Interleukin-1 (IL-1), can inhibit triglyceride synthesis and, at the same time, can promote insulin resistance in various target tissue, highlighting the complex interplay between metabolic and biochemical inflammatory pathways in CV [ 19 ]. These markers have also been found to be elevated in patients receiving statin therapy, despite their cholesterol levels being well controlled [ 9 , 11 , 12 , 13 , 14 , 15 , 16 , 17 ]. This scenario suggests that inflammation may indeed play a significant role in cardiovascular risk, even in patients who are already taking statins [ 11 , 12 , 13 , 14 , 15 , 16 , 17 ].…”